久久日激情网,91视屏亚洲,日韩精品电影在线

BeOne(BeiGene) Q2 2025 Interim Financial Report BeiGene BeiGene reported a net profit of 450 million yuan for H1 2025, marking its first interim profit since A-share listing. Strong product sales and revised revenue and margin forecasts signal sustainable growth.
BeiGene's Q1 2025 Financial report Market Trend BeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
BeiGene and MSN Pharmaceuticals Settle Patent Lawsuit on Zanubrutinib Generic BeiGene BeiGene and MSN Pharmaceuticals settle patent lawsuit over Zanubrutinib generic, extending patent protection until 2037. The settlement reaffirms BeiGene’s confidence in protecting its groundbreaking BTK inhibitor.
China's First! BeiGene's PD-1 Inhibitor Baizean? Approved for 14th Indication BeiGene BeiGene's PD-1 inhibitor Baizean? (Tislelizumab) has been approved in China for its 14th indication, marking it as the first PD-1 drug for perioperative immunotherapy in stage II-III non-small cell lung cancer. This new treatment improves event-free survival, offering hope for better outcomes.
The Various Ways of Bringing Innovative Drugs to Market Chinese Pharmaceutical Market Chinese innovative drug companies are nearing profitability, with diverse strategies like global expansion and strategic partnerships. As they release promising semi-annual reports, these companies showcase the growing potential for original innovation and sustained success in the global market.

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水